Loading…
Kyntra Bio, Inc. is projected to rise to $9.07 by 2027, a +19% move from its current price of $7.61. KYNB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $7.44 | $7.61 | $7.78 | +0.07% |
| Jul 13 | $7.38 | $7.61 | $7.86 | +0.13% |
| Jul 14 | $7.33 | $7.62 | $7.92 | +0.20% |
| Jul 15 | $7.29 | $7.62 | $7.98 | +0.26% |
| Jul 16 | $7.25 | $7.63 | $8.03 | +0.33% |
| Jul 17 | $7.22 | $7.63 | $8.07 | +0.39% |
| Jul 18 | $7.20 | $7.64 | $8.11 | +0.46% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.20 | $7.64 | $8.11 | +0.46% |
| Week 2 | $7.05 | $7.68 | $8.35 | +0.92% |
| Week 3 | $6.95 | $7.71 | $8.55 | +1.39% |
| Week 4 | $6.87 | $7.75 | $8.73 | +1.85% |
| Week 5 | $6.81 | $7.78 | $8.89 | +2.32% |
| Week 6 | $6.75 | $7.82 | $9.05 | +2.79% |
| Week 7 | $6.71 | $7.85 | $9.20 | +3.27% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Kyntra Bio, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.
The company is developing FG-3246, an antibody-drug conjugate targeting CD46, for metastatic castration-resistant prostate cancer and other cancers.
It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.
The company was renamed to Kyntra Bio, Inc. in January 2026 after previously being FibroGen, Inc. It was incorporated in 1993 and is headquartered in San Francisco, California.
Kyntra Bio, Inc. (KYNB) is currently trading at $7.55 with a market capitalization of $30.56M. Its rank is 4775.
The price outlook shows potential upside over the coming years, with a 2026 average of $7.55 and a path to higher averages by 2027 and beyond, including a 2027 average of $8.77 and a 2030 average of $9.70, rising further to a 2050 average of $37.01.
The forecast also provides higher upside scenarios, with 2029 average $9.67 and 2032 average $12.86, leading to much higher long-term targets such as 2040 average $22.24 and 2050 average $37.01, accompanied by progressively larger max values and ROI figures.
A major floor 17.3% below — a decisive break under it would weaken the trend.
The nearest floor, 12.8% below — buyers have tended to step in here.
Price is pressing into resistance (0.3% away) — a breakout level to watch.
A major ceiling 9.0% above — clearing it would confirm fresh momentum.
Key KYNB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KYNB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.44 | Buy | $7.47 | Buy |
| MA 10 | $7.45 | Buy | $7.39 | Buy |
| MA 20 | $7.17 | Buy | $7.25 | Buy |
| MA 50 | $7.03 | Buy | $7.13 | Buy |
| MA 100 | $7.08 | Buy | $7.34 | Buy |
| MA 200 | $8.32 | Sell | $8.22 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.93 | Neutral |
| Stoch RSI (14) | 55.43 | Neutral |
| CCI (20) | 104.78 | Buy |
| Williams %R (14) | -3.33 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 9.11 | Buy |
| Bollinger %B (20,2) | 0.86 | Neutral |
| Stochastic %K (14) | 96.67 | Sell |
| TRIX (15) | 0.25 | Buy |
| Awesome (5,34) | 0.40 | Buy |
| Ultimate (7,14,28) | 58.69 | Neutral |
| Momentum (10) | 0.66 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 7.46 | Buy |
| ADX (14) | 15.96 | Neutral |
| ATR (14) | 0.15 | Info |
The 30-day technical picture is bullish, with RSI14 at 70 indicating positive momentum.
Key moving averages show the near-term trend, as the SMA50 is $6.98 and the SMA200 is $8.44.
Support is identified at $6.63 and resistance at $7.55, framing a 30-day price range from $6.49 to $8.79.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $6.46 | $7.61 | $10.58 | 0% | Neutral | |
| $7.34 | $9.07 | $11.79 | +19% | Neutral | |
| $7.43 | $9.40 | $12.61 | +24% | Bullish | |
| $8.19 | $10.55 | $14.51 | +39% | Bullish | |
| $8.25 | $10.81 | $15.17 | +42% | Bullish | |
| $9.28 | $12.34 | $17.64 | +62% | Bullish | |
| $11.19 | $15.08 | $21.91 | +98% | Bullish | |
| $11.59 | $15.82 | $23.33 | +108% | Bullish | |
| $12.69 | $17.54 | $26.22 | +131% | Bullish | |
| $12.91 | $18.05 | $27.34 | +137% | Bullish | |
| $18.81 | $27.72 | $44.29 | +264% | Bullish | |
| $30.91 | $49.78 | $86.08 | +555% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $6.46 | $7.61 | $9.22 | +0.00% |
| August 2026 | $6.85 | $8.05 | $9.69 | +5.88% |
| September 2026 | $6.83 | $8.07 | $9.81 | +0.27% |
| October 2026 | $6.84 | $8.13 | $9.95 | +0.68% |
| November 2026 | $7.06 | $8.42 | $10.37 | +3.58% |
| December 2026 | $7.13 | $8.54 | $10.58 | +1.39% |
Click any year to see its month-by-month KYNB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Kyntra Bio, Inc.'s 2026 outlook centres on $7.61, within a $6.46 to $10.58 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, KYNB could reach as high as $11.79, with a base case around $9.07 and support toward $7.34 — roughly +19% from $7.61. Price action looks broadly range-bound.
Expect KYNB to range from $7.43 to $12.61 through 2028. The $9.40 average target implies a +24% move from current prices. That is up +4% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The KYNB price prediction for 2029 points to an average of $10.55 (low $8.19, high $14.51) — a potential gain of +39% on today's $7.61. Momentum favours further upside here.
In 2030, KYNB is projected to trade between $8.25 and $15.17, averaging $10.81 — a potential gain of +42% from today's $7.61. That is up +2% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Kyntra Bio, Inc.'s 2031 outlook centres on $12.34, within a $9.28 to $17.64 range. That is up +14% on the projected 2030 average. That marks a +62% change versus current levels. Momentum favours further upside here.
By 2032, KYNB could reach as high as $21.91, with a base case around $15.08 and support toward $11.19 — roughly +98% from $7.61. Buyers look set to stay in control over this stretch.
Expect KYNB to range from $11.59 to $23.33 through 2033. The $15.82 average target implies a +108% move from current prices. That is up +5% on the projected 2032 average. Momentum favours further upside here.
The KYNB price prediction for 2034 points to an average of $17.54 (low $12.69, high $26.22) — a potential gain of +131% on today's $7.61. Buyers look set to stay in control over this stretch.
In 2035, KYNB is projected to trade between $12.91 and $27.34, averaging $18.05 — a potential gain of +137% from today's $7.61. That is up +3% on the projected 2034 average. Momentum favours further upside here.
Kyntra Bio, Inc.'s 2040 outlook centres on $27.72, within a $18.81 to $44.29 range. That is up +54% on the projected 2035 average. That marks a +264% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, KYNB could reach as high as $86.08, with a base case around $49.78 and support toward $30.91 — roughly +555% from $7.61. Momentum favours further upside here.
Investing $1,000 in KYNB today (≈ 131.492439 KYNB) could be worth
$6,545.64
+$5,545.64 (+555%) by 2050 · US Dollar
Based on the average projected KYNB price of $49.78 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KYNBwould be worth at today's price.
$1,000 invested in KYNB on Jul 10, 2025 (≈ 136.054424 KYNB) would be worth
$1,034.69
+$34.69 (+3.5%) today · 1.03× · US Dollar
Based on a KYNB entry price of $7.35 vs. today's $7.61.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.63 | $996.72 | -0.3% |
| 1 month ago | $6.69 | $1,136.77 | +13.7% |
| 3 months ago | $7.17 | $1,060.67 | +6.1% |
| 6 months ago | $9.07 | $838.48 | -16.2% |
| 1 year ago | $7.35 | $1,034.69 | +3.5% |
| All time (5.0y) ago | $634.75 | $11.98 | -98.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KYNB forecast.
Our base-case forecast reaches $15.00 around 2032.
Implied market cap at $15.00: $60.72M
The multi-year forecast shows a path of rising averages and growth in potential returns, with 2026 forecasts neutral (min $6.46, avg $7.55, max $10.42; ROI 0) and sentiment Neutral. By 2027 the average price is $8.77 with ROI 16.2 and Neutral sentiment, followed by 2028 at $8.93 with ROI 18.3 and Neutral sentiment, and 2029 at $9.67 with ROI 28.1 and Bullish sentiment.
From 2030 onward, the trajectory strengthens: 2030 average $9.70, ROI 28.5, Bullish; 2031 average $10.74, ROI 42.3; 2032 average $12.86, ROI 70.3; 2033 average $13.56, ROI 79.5; 2034 average $14.89, ROI 97.2; 2035 average $14.94, ROI 97.8; 2040 average $22.24, ROI 194.6; and 2050 average $37.01, ROI 390.2, all with Bullish sentiment.
These are estimates, not guarantees, and actual results depend on multiple factors, including market conditions and company milestones.
Tap a question to reveal the answer.
In 2030, the forecast shows min $7.38, avg $9.70, max $13.67, with ROI 28.5 and sentiment BULLISH.
The 2026 forecast is Neutral with an average of $7.55 and ROI 0. From 2027 onward, forecasts show rising averages and Bullish sentiment, with ROIs climbing to 16.2% in 2027, 18.3% in 2028, up to 390.2% by 2050. These are estimates, not guarantees.
Yes. The 2033 max is $20.09, and higher years show max values such as 2034 at $22.37, 2040 at $35.75, and 2050 at $64.45.
Current price is $7.55 and market cap is $30.56M.
The 30-day price range is from $6.49 to $8.79.
Kyntra Bio, Inc. Community Discussion
0Share your Kyntra Bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.